Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference
Cue Biopharma, a clinical-stage biopharmaceutical company, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 11:20 a.m. EDT. The discussion will cover clinical updates on CUE-101, targeting HPV+ recurrent/metastatic head and neck cancer. The company also plans to highlight milestones for its pipeline, including CUE-102, with an IND filing expected by the end of Q1 2022. The webcast will be available live and archived for 30 days on their website.
- None.
- None.
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the Oppenheimer 32nd Annual Healthcare Conference being held virtually March 15-17.
The Company will provide an updated corporate overview and discuss clinical progress from its ongoing clinical trials with CUE-101, its lead and representative drug product candidate from the IL-2 based CUE-100 series in development for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The Company will also discuss anticipated milestones and additional IL-2 based CUE-100 series pipeline progress, including its second IL-2 based candidate CUE-102 with an Investigational New Drug (IND) filing planned for the end of the first quarter 2022.
Presentation Details
| Oppenheimer 32nd Annual Healthcare Conference | |
| Date and Time: | Thursday, March 17, 2022 at 11:20 a.m. EDT |
| Webcast link: | https://wsw.com/webcast/oppenheimer20/cue/2529702 |
A live and archived webcast of the presentation will be available in the Investor and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the potential for CUE-101 to treat HPV+ R/M HNSCC; the company’s plans to select the CUE-101 monotherapy Phase 2 clinical trial dose in mid-2021; the company’s plans to report initial Phase 1 results of the CUE-101 +pembrolizumab combination trial in the second half of 2021; anticipated initiation of the CUE-101 Phase 2 clinical trial to evaluate effects of CUE-101 on tumor microenvironment and expand patient access and market potential for CUE-101 in the second half of 2021; the potential of the CUE 100 series for anti-tumor activity; the potential benefits of the company’s Immuno-STAT™ platform biologics; the anticipated results of the company’s drug development efforts, including study results; the company’s expectations regarding regulatory developments and expected future operating results; and statements regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s limited operating history, limited cash and history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company’s operations and clinical trials; negative or inconclusive results from the company’s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com
FAQ
When will Cue Biopharma present at the Oppenheimer 32nd Annual Healthcare Conference?
What is the focus of Cue Biopharma's presentation at the conference?
What are the upcoming milestones for Cue Biopharma's drug candidates?
How can investors access the presentation by Cue Biopharma?
What is CUE-101, as mentioned in the Cue Biopharma press release?
